Etanercept: An overview (Q35190102)

7 August 2017

1 reference

title

Etanercept: An overview (English)

1 reference

7 August 2017

Ben Goffe

1

1 reference

7 August 2017

Jennifer Clay Cather

series ordinal

2

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Journal of the American Academy of Dermatology

7 August 2017

published in

1 reference

7 August 2017

volume

49

1 reference

7 August 2017

issue

2 Suppl

1 reference

7 August 2017

page(s)

S105-11

1 reference

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

Inflammatory skin diseases, T cells, and immune surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

7 January 2021

Cytokines in psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

The immunologic basis for the treatment of psoriasis with new biologic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

The cytokine network in psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor .alpha. induced receptor aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

Tuberculosis and treatment with infliximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

Drug-induced systemic lupus erythematosus associated with etanercept therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

Etanercept-induced subacute cutaneous lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.554

7 January 2021

Identifiers

DOI

10.1016/MJD.2003.554

1 reference

7 August 2017

1 reference